Why does the injectable form of DHB have higher bioavailability than oral dihydroboldenone?

Injectable DHB bypasses hepatic first-pass metabolism entirely, meaning the full injected dose enters systemic circulation rather than being degraded by liver enzymes before reaching target tissues. Oral non-17-alpha-alkylated androgens like dihydroboldenone are extensively cleared during first pass, with published analogues showing oral bioavailability below 10%, while intramuscular injection achieves near-complete systemic exposure.

What role does first-pass metabolism play in reducing the effectiveness of oral DHB compounds?

First-pass metabolism occurs when an orally ingested compound travels via portal blood to the liver before entering general circulation. Cytochrome P450 enzymes in the liver degrade a large fraction of non-alkylated androgens at this stage. For dihydroboldenone specifically, this pre-systemic clearance dramatically reduces the amount of active compound available to androgen-sensitive tissues, making oral formats pharmacokinetically inefficient compared to direct intramuscular delivery.

How does absorption differ after intramuscular injection of dihydroboldenone compared to oral intake?

After intramuscular injection, DHB forms an intramuscular depot from which the compound is gradually absorbed into capillary and lymphatic networks upstream of the liver, producing sustained plasma levels without hepatic pre-clearance. Oral absorption, by contrast, passes through the gastrointestinal epithelium and portal circulation, exposing the compound to both gut-wall enzymes and hepatic first-pass degradation before it reaches systemic blood.

How should Master Pharma DHB 150mg/ml be drawn and injected using an insulin syringe or standard needle?

At 150mg/ml, Master Pharma DHB is among the most concentrated DHB formulations available in a 10ml vial format. A standard 21–23 gauge intramuscular needle (1–1.5 inch) is recommended for drawing and injection; insulin syringes are not appropriate for oil-based intramuscular compounds. Draw with a larger gauge needle, swap to the injection gauge to preserve sharpness, and administer slowly into a large muscle group.

How should the 10ml vial be stored after opening to maintain sterility and concentration integrity?

After the rubber septum is first punctured, store the vial upright at room temperature (15–25°C), away from direct light and heat sources. Do not refrigerate oil-based injectable solutions, as cooling can cause the compound to precipitate or the oil to thicken, affecting accurate dosing. Use a fresh sterile needle for each draw, and inspect the solution visually before each use — discard if particulates or unusual colour changes appear. (2) angle_used

Pharma Grade

Master Pharma

DHB 150mg/ml 10ml Vial by Master Pharma

Name: DHB
Brand: Master Pharma
SKU: INJ-DHB-MAS-150-003
Price: 48.00 EUR
Availability: InStock

Master Pharma DHB delivers dihydroboldenone at a concentrated 150mg/ml in a sterile 10ml vial — a form engineered to bypass the hepatic first-pass metabolism that severely limits the practical bioavailability of oral dihydroboldenone preparations. Because the compound is administered intramuscularly, virtually the entire injected dose enters systemic circulation intact, a pharmacokinetic advantage no oral DHB formulation can replicate. Batch-released under GMP protocols; each vial carries independent HPLC concentration verification and LAL endotoxin certification before distribution.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Near-complete systemic delivery achieved through intramuscular administration, bypassing gut and liver degradation
150mg/ml concentration reduces total injection volume per cycle week compared to lower-dosed alternatives
HPLC-verified label accuracy ensures each dose reflects the stated 150mg/ml rather than degraded hepatic residue
LAL endotoxin testing at finished-vial stage confirms sterility for a compound administered repeatedly
10ml multi-dose vial format supports full cycle lengths without mid-cycle vial changes
No aromatisation to estrogen reported in pharmacological literature — lean tissue support without water retention
Independent third-party batch certificates available, allowing practitioners to cross-check concentration before use

Phase	Dosage	Note
Introductory (Weeks 1–2)	150–200mg/week (1–1.33ml)	Lower starting volume allows assessment of individual injection-site tolerance at 150mg/ml concentration; bioavailability is immediate from first injection
Main Cycle (Weeks 3–10)	300–400mg/week (2–2.67ml)	Split across 2–3 injections per week to distribute volume; full systemic bioavailability maintained at each injection point without first-pass losses
Taper / Transition (Weeks 11–12)	150mg/week (1ml)	Gradual reduction leverages the injectable's precise dose-response relationship; timing of final injection informs PCT scheduling

Key takeaways

Choose injectable DHB to eliminate hepatic first-pass metabolism losses entirely.
Expect near-complete systemic exposure unavailable from any oral dihydroboldenone format.
Verify each batch via HPLC before committing to a concentration-dependent dosing protocol.
Store the opened 10ml vial at room temperature and protect from direct light.
Select 150mg/ml concentration to reduce injection volume per weekly dose.

What Makes Injectable DHB Fundamentally More Bioavailable Than Oral Formats

Master Pharma DHB is a sterile intramuscular solution that delivers dihydroboldenone into systemic circulation with near-complete efficiency — a property that separates injectable DHB categorically from any oral formulation of the same molecule. The injectable route eliminates hepatic first-pass metabolism entirely: when a compound is swallowed, portal venous blood carries it directly to the liver, where cytochrome P450 enzymes can degrade a substantial fraction before it ever reaches target tissues. With intramuscular injection, the compound disperses into the interstitial fluid, is absorbed into lymphatic and capillary networks, and enters the bloodstream upstream of hepatic clearance.

First-Pass Metabolism and Why It Matters for DHB Specifically

Oral delivery of non-17-alpha-alkylated androgens — the structural class to which dihydroboldenone belongs — suffers particularly high pre-systemic clearance. Published pharmacokinetic literature on structurally analogous steroids documents oral bioavailability figures below 10% for non-alkylated androgens compared to near-complete systemic exposure via intramuscular injection (reference framework: pharmacokinetic modelling consistent with FDA guidance on parenteral vs. oral bioequivalence). Master Pharma's 150mg/ml concentration compounds this advantage: each millilitre delivers a validated dose that reaches circulation intact, so the stated label claim translates directly into plasma exposure rather than being eroded by gut-wall and hepatic enzymes.

Absorption Kinetics After Intramuscular Administration

Following injection into the gluteal or deltoid muscle, the ester-bound compound forms a subcutaneous depot from which lipase and esterase activity gradually liberates free dihydroboldenone into plasma. This depot-mediated absorption produces a controlled concentration-time curve with none of the erratic peak-trough variability associated with gastrointestinal absorption. Intramuscular administration achieves systemic bioavailability approaching 100% in parenteral pharmacokinetic models, a benchmark unattainable through any currently documented oral DHB delivery system.

Quality Assurance at 150mg/ml: Why Concentration Demands Verification

Master Pharma subjects every production batch to HPLC quantification at the finished-vial stage, confirming that the 150mg/ml label claim is met within tight tolerances. LAL (Limulus Amebocyte Lysate) endotoxin screening validates sterility at a concentration level where any contamination risk is amplified by the injection frequency typical of DHB protocols. Independent third-party laboratory verification of each lot provides documentation that practitioners can cross-reference against the declared concentration — a transparency standard that reinforces the bioavailability argument: precise dosing only has meaning when the stated concentration is analytically confirmed.

Usage

Confirm the vial label reads 150mg/ml and check the batch-specific HPLC certificate matches the lot number printed on the vial before first use.
Warm the vial briefly in a clean warm-water bath (not microwave) if ambient temperature has thickened the oil, to ensure accurate draw at 150mg/ml concentration.
Draw the calculated volume using a 21-gauge draw needle; swap to a fresh 23-gauge, 1–1.5 inch injection needle to maintain sharpness for intramuscular administration.
Select a large muscle group — gluteus maximus or vastus lateralis — to accommodate the oil volume; rotate injection sites across the week to reduce accumulation at any single point.
Inject slowly over 30–60 seconds to minimise injection-site discomfort associated with concentrated oil-based solutions; aspirate briefly before injection when injecting into the glute.
Recap the vial with a sterile cap after each draw, store upright at room temperature away from light, and document the injection date and volume drawn to track remaining content across the 10ml vial.

Warnings

Contraindications: Do not use if you have existing hepatic impairment, cardiovascular disease, prostate pathology, or are currently taking anticoagulant therapy. Women who are pregnant, breastfeeding, or of childbearing age should not use this product. Individuals under 21 years of age should not administer anabolic androgenic compounds.

Side Effects: Potential androgenic effects include accelerated hair follicle recession in genetically predisposed individuals, acne along the back and shoulders, and increased sebaceous activity. Suppression of endogenous testosterone production is expected with sustained use. Injection-site discomfort or localised inflammation may occur, particularly at 150mg/ml concentration if injection technique is inconsistent.

Monitoring: Haematocrit, lipid panel (LDL/HDL ratio), and liver enzyme markers (ALT, AST) should be assessed at baseline and at four-week intervals during the cycle. Blood pressure monitoring is advisable given androgenic compounds' documented influence on vascular tone. PSA screening is recommended for users over 35.

PCT: Initiate post-cycle therapy once plasma DHB levels have cleared sufficiently, guided by the ester's release profile and the timing of the final injection. Standard PCT agents such as tamoxifen or clomiphene are appropriate to restore hypothalamic-pituitary-gonadal axis function. Allow sufficient clearance time before beginning PCT to avoid counterproductive overlap with residual circulating compound.

Frequently asked questions

Why does the injectable form of DHB have higher bioavailability than oral dihydroboldenone?: Injectable DHB bypasses hepatic first-pass metabolism entirely, meaning the full injected dose enters systemic circulation rather than being degraded by liver enzymes before reaching target tissues. Oral non-17-alpha-alkylated androgens like dihydroboldenone are extensively cleared during first pass, with published analogues showing oral bioavailability below 10%, while intramuscular injection achieves near-complete systemic exposure.
What role does first-pass metabolism play in reducing the effectiveness of oral DHB compounds?: First-pass metabolism occurs when an orally ingested compound travels via portal blood to the liver before entering general circulation. Cytochrome P450 enzymes in the liver degrade a large fraction of non-alkylated androgens at this stage. For dihydroboldenone specifically, this pre-systemic clearance dramatically reduces the amount of active compound available to androgen-sensitive tissues, making oral formats pharmacokinetically inefficient compared to direct intramuscular delivery.
How does absorption differ after intramuscular injection of dihydroboldenone compared to oral intake?: After intramuscular injection, DHB forms an intramuscular depot from which the compound is gradually absorbed into capillary and lymphatic networks upstream of the liver, producing sustained plasma levels without hepatic pre-clearance. Oral absorption, by contrast, passes through the gastrointestinal epithelium and portal circulation, exposing the compound to both gut-wall enzymes and hepatic first-pass degradation before it reaches systemic blood.
How should Master Pharma DHB 150mg/ml be drawn and injected using an insulin syringe or standard needle?: At 150mg/ml, Master Pharma DHB is among the most concentrated DHB formulations available in a 10ml vial format. A standard 21–23 gauge intramuscular needle (1–1.5 inch) is recommended for drawing and injection; insulin syringes are not appropriate for oil-based intramuscular compounds. Draw with a larger gauge needle, swap to the injection gauge to preserve sharpness, and administer slowly into a large muscle group.
How should the 10ml vial be stored after opening to maintain sterility and concentration integrity?: After the rubber septum is first punctured, store the vial upright at room temperature (15–25°C), away from direct light and heat sources. Do not refrigerate oil-based injectable solutions, as cooling can cause the compound to precipitate or the oil to thicken, affecting accurate dosing. Use a fresh sterile needle for each draw, and inspect the solution visually before each use — discard if particulates or unusual colour changes appear. (2) angle_used

Manufacturer

Master Pharma's quality framework for its injectable steroid lines is anchored by a structured programme of independent third-party laboratory verification — a practice applied systematically to every finished batch before distribution release. For DHB 150mg/ml, this means that concentration accuracy and endotoxin status are not self-certified internally but cross-validated by external laboratories whose testing records are maintained as lot-specific documentation. The third-party verification model serves a specific function at high concentrations: at 150mg/ml, even minor deviations from label claim carry proportionally greater dosing consequences than at lower-concentration formats, making external quantitative confirmation — conducted by HPLC at the finished-vial stage — a non-negotiable part of the release chain rather than an optional quality add-on.

Product details

Brand	Master Pharma
Active ingredient	dihydroboldenone
Also known as	1-Testosteronee, Dihydroboldenon, 1-Test Cyp 100, DHB, Master Pharma 1-Testosteronee
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-DHB-MAS-150-003

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

1-Test Cyp 100 100mg/ml 10ml Vial by Dragon-Pharma

Dihydroboldenone Cypionate (DHB) is a 5-alpha-reduced, non-aromatizing androgenic-anabolic steroid delivered here at 100 mg/ml in a 10 ml multi-dose vial — its defining characteristic being a direct, high-affinity bond to the androgen receptor without estrogen conversion. Unlike base testosterone, DHB retains all anabolic signalling through the androgen receptor while bypassing aromatase, making receptor-mediated tissue response its exclusive mechanism of action. Every production lot of Dragon-Pharma 1-Test Cyp 100 is verified through a dual analytical gate: HPLC quantification of the finished vial against a certified DHB reference standard, followed by LAL endotoxin testing under documented GMP conditions.

€46.00

DHB 100mg/ml 10x1ml Ampoules by Imperia Laboratories

Long-Acting Formula

DHB 100mg/ml 10x1ml Ampullen by Imperia Laboratories

Dihydroboldenone (DHB) at 100 mg/ml in single-dose ampoule format is characterised principally by its pharmacokinetic profile: an esterless parent compound paired with a short-chain ester that determines how rapidly the active steroid enters systemic circulation and how long meaningful plasma concentrations persist. The acetate or base form of DHB exhibits a markedly shorter plasma half-life than longer-ester analogues, which translates directly into injection frequency decisions and peak-to-trough ratio management during a cycle. Quality assurance at Imperia Laboratories is enforced through reversed-phase HPLC quantification of active-ingredient concentration and LAL endotoxin testing on every production batch — each ampoule sealed and released only after both gates are passed.

€48.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00